Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.

A new study finds that three existing drugs can force leukemia cells into necroptosis, activating a strong immune response.

Radiopharm completes enrollment for second cohort of patients in phase 1 dose escalation trial of 177Lu-RAD204 in PD-L1 positive advanced cancers: Sydney Saturday, November 15, 20 ...

Researchers uncovered a powerful weakness in lung cancer by shutting down a protein that helps tumors survive stress. When this protein, FSP1, was blocked, lung tumors in mice shrank dramatically, ...

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session ...

At the European Society of Medical Oncology Congress in October 2025 in Berlin, Germany, researchers shared results from the BEACON study, which is the first real-world look at how integrin beta-6 ...

(Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead ...

GT-02287 improves mitochondrial function by facilitating GCase trafficking to the mitochondria in patient-derived fibroblasts ...

The emergence of cancer drug resistance remains one of the most pressing problems in cancer care and there is a critical need ...

The targeted radiotherapies for cancer market is experiencing significant growth, driven by advancements in technology and ...

Amgen announced today that the U.S. Food and Drug Administration (FDA) has granted full approval to IMDELLTRA® (tarlatamab-dlle) for the treatment of adult patients with extensive stage small cell ...

Phage therapy is reshaping our understanding of how targeted viruses can reset the gut microbiome, offering a precise, ...